An investigation on behalf of investors in Blueprint Medicines Corporation (NASDAQ:BPMC) shares over potential wrongdoing at Blueprint Medicines Corporation was announced.
San Diego, CA -- (SBWIRE) -- 10/12/2022 -- Certain directors of Blueprint Medicines Corporation are under investigation over potential breaches of fiduciary duties.
Investors who purchased shares of Blueprint Medicines Corporation (NASDAQ: BPMC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Blueprint Medicines Corporation (directors breached their fiduciary duties and caused damage to the company and its shareholders.
Cambridge, MA based Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.
Blueprint Medicines Corporation reported that its annual Total Revenue declined from $793.73 million in 2020 to $180.08 million in 2021, and that its Net Income of $313.88 million in 2020 turned into a Net Loss of $644.08 million in 2021.
On August 17, 2022, before trading hours, Blueprint Medicines Corporation announced top-line results from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib) in patients with non-advanced systemic mastocytosis (SM). The results showed a deterioration in the absolute improvement in the symptom score from 15.6 points in this most recent trial versus 19.7 in Phase 1.
Shares of Blueprint Medicines Corporation (NASDAQ: BPMC) declined from $73.03 per share on August 12, 2022, to as low as $52.00 per share on August 17, 2022.
Those who purchased shares of Blueprint Medicines Corporation (NASDAQ: BPMC) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.